{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:06:50Z","timestamp":1786133210783,"version":"build-2736575974"},"reference-count":68,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA175382"],"award-info":[{"award-number":["R01CA175382"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 HL132325"],"award-info":[{"award-number":["R01 HL132325"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","award":["R01HL136363"],"award-info":[{"award-number":["R01HL136363"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","award":["R01HL080442"],"award-info":[{"award-number":["R01HL080442"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","award":["T32 HL007224-40"],"award-info":[{"award-number":["T32 HL007224-40"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","award":["GM086308-06A1"],"award-info":[{"award-number":["GM086308-06A1"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["JASN"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n                    <jats:title>Significance Statement<\/jats:title>\n                    <jats:p>Patients with CKD are at a markedly higher risk of thrombosis after vascular procedures. Uremic solutes, such as indoxyl sulfate and kynurenine, are important contributors to this complication through tissue factor (TF), a trigger of the extrinsic coagulation cascade. This study examines the role of indoleamine 2,3-dioxygenase-1 (IDO-1), a key enzyme in kynurenine biogenesis, in thrombotic complications in CKD. Using genomic and pharmacological approaches, this study demonstrates that IDO-1 is a critical regulator of TF and thrombosis after vascular injury in CKD mice. Indoxyl sulfate upregulates IDO-1, creating a feedback-forward loop. IDO-1 activity was higher in patients with CKD, who developed thrombosis after vascular interventions. This study identifies IDO-1 as a therapeutic target and uncovers crosstalk between uremic solutes, perpetuating their toxic effect.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>CKD, characterized by retained uremic solutes, is a strong and independent risk factor for thrombosis after vascular procedures . Urem ic solutes such as indoxyl sulfate (IS) and kynurenine (Kyn) mediate prothrombotic effect through tissue factor (TF). IS and Kyn biogenesis depends on multiple enzymes, with therapeutic implications unexplored. We examined the role of indoleamine 2,3-dioxygenase-1 (IDO-1), a rate-limiting enzyme of kynurenine biogenesis, in CKD-associated thrombosis after vascular injury.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      IDO-1 expression in mice and human vessels was examined. IDO-1\n                      <jats:sup>\u2212\/\u2212<\/jats:sup>\n                      mice, IDO-1 inhibitors, an adenine-induced CKD, and carotid artery injury models were used.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Both global IDO-1\n                      <jats:sup>\u2212\/\u2212<\/jats:sup>\n                      CKD mice and IDO-1 inhibitor in wild-type CKD mice showed reduced blood Kyn levels, TF expression in their arteries, and thrombogenicity compared with respective controls. Several advanced IDO-1 inhibitors downregulated TF expression in primary human aortic vascular smooth muscle cells specifically in response to uremic serum. Further mechanistic probing of arteries from an IS-specific mouse model, and CKD mice, showed upregulation of IDO-1 protein, which was due to inhibition of its polyubiquitination and degradation by IS in vascular smooth muscle cells. In two cohorts of patients with advanced CKD, blood IDO-1 activity was significantly higher in sera of study participants who subsequently developed thrombosis after endovascular interventions or vascular surgery.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Leveraging genetic and pharmacologic manipulation in experimental models and data from human studies implicate IS as an inducer of IDO-1 and a perpetuator of the thrombotic milieu and supports IDO-1 as an antithrombotic target in CKD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1681\/asn.2020091310","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T17:10:50Z","timestamp":1635527450000},"page":"2834-2850","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":23,"title":["Indoleamine 2,3-dioxygenase-1, a Novel Therapeutic Target for Post-Vascular Injury Thrombosis in CKD"],"prefix":"10.1681","volume":"32","author":[{"given":"Joshua A.","family":"Walker","sequence":"first","affiliation":[{"name":"Renal Section, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts"},{"name":"Whitaker Cardiovascular Institute, Boston University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Richards","sequence":"additional","affiliation":[{"name":"Renal Section, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5439-6501","authenticated-orcid":false,"given":"Stephen A.","family":"Whelan","sequence":"additional","affiliation":[{"name":"Chemical Instrumentation Center, Boston University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Bok","family":"Yoo","sequence":"additional","affiliation":[{"name":"Renal Section, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa L.","family":"Russell","sequence":"additional","affiliation":[{"name":"Renal Section, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nkiruka","family":"Arinze","sequence":"additional","affiliation":[{"name":"Department of Surgery, Boston University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saran","family":"Lotfollahzadeh","sequence":"additional","affiliation":[{"name":"Renal Section, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Napoleon","sequence":"additional","affiliation":[{"name":"Renal Section, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2097-6882","authenticated-orcid":false,"given":"Mostafa","family":"Belghasem","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Lee","sequence":"additional","affiliation":[{"name":"Chemical Instrumentation Center, Boston University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Dember","sequence":"additional","affiliation":[{"name":"Renal-Electrolyte and Hypertension Division, Center for Clinical Epidemiology and Biostatistics, Philadelphia, Pennsylvania"},{"name":"Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katya","family":"Ravid","sequence":"additional","affiliation":[{"name":"Whitaker Cardiovascular Institute, Boston University, Boston, Massachusetts"},{"name":"Department of Medicine, Boston University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6663-6058","authenticated-orcid":false,"given":"Vipul C.","family":"Chitalia","sequence":"additional","affiliation":[{"name":"Renal Section, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts"},{"name":"Veteran Affairs Boston Healthcare System, Boston, Massachusetts"},{"name":"Institute of Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,11]]},"reference":[{"key":"B1-20240826","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1053\/ajkd.1998.v32.pm9820470","article-title":"Clinical epidemiology of cardiovascular disease in chronic renal disease","volume":"32","author":"Foley","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"B2-20240826","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/jth.13904","article-title":"Chronic kidney disease and bleeding risk in patients at high cardiovascular risk: A cohort study","volume":"16","author":"Ocak","year":"2018","journal-title":"J Thromb Haemost"},{"key":"B3-20240826","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1161\/CIRCULATIONAHA.109.903955","article-title":"Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: Observations from the Registry of Stent Thrombosis for Review and Reevaluation (RESTART)","volume":"122","author":"Kimura","year":"2010","journal-title":"Circulation"},{"key":"B4-20240826","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1111\/j.1755-5922.2010.00186.x","article-title":"Stent thrombosis: Risk assessment and prevention","volume":"28","author":"Motovska","year":"2010","journal-title":"Cardiovasc Ther"},{"key":"B5-20240826","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.amjcard.2006.02.039","article-title":"Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up","volume":"98","author":"Park","year":"2006","journal-title":"Am J Cardiol"},{"key":"B6-20240826","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/ccd.21887","article-title":"Incidence, predictors, and outcome of reinfarction and stent thrombosis within one year after primary percutaneous coronary intervention for ST-elevation myocardial infarction","volume":"73","author":"Fokkema","year":"2009","journal-title":"Catheter Cardiovasc Interv"},{"key":"B7-20240826","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1001\/jama.293.17.2126","article-title":"Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents","volume":"293","author":"Iakovou","year":"2005","journal-title":"JAMA"},{"key":"B8-20240826","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ahj.2009.01.009","article-title":"Chronic kidney disease and dipstick proteinuria are risk factors for stent thrombosis in patients with myocardial infarction","volume":"157","author":"Lambert","year":"2009","journal-title":"Am Heart J"},{"key":"B9-20240826","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0002-9149(00)01442-9","article-title":"Evaluation of long-term survival after successful percutaneous coronary intervention among patients with chronic renal failure","volume":"87","author":"Ting","year":"2001","journal-title":"Am J Cardiol"},{"key":"B10-20240826","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1161\/01.CIR.0000016051.33225.33","article-title":"Outcomes of patients with chronic renal insufficiency in the bypass angioplasty revascularization investigation","volume":"105","author":"Szczech","year":"2002","journal-title":"Circulation"},{"key":"B11-20240826","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1161\/CIRCINTERVENTIONS.109.852178.109.852178","article-title":"Drug-eluting stent thrombosis in routine clinical practice: Two-year outcomes and predictors from the TAXUS ARRIVE registries","volume":"2","author":"Lasala","year":"2009","journal-title":"Circ Cardiovasc Interv"},{"key":"B12-20240826","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1525-139X.2003.16048.x","article-title":"Thrombosis in end-stage renal disease","volume":"16","author":"Casserly","year":"2003","journal-title":"Semin Dial"},{"key":"B13-20240826","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/sdi.12255","article-title":"Thrombosis in the uremic milieu: Emerging role of \u201cthrombolome\u201d","volume":"28","author":"Shashar","year":"2015","journal-title":"Semin Dial"},{"key":"B14-20240826","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41581-021-00408-4","article-title":"Uraemic solutes as therapeutic targets in CKD-associated cardiovascular disease","volume":"17","author":"Ravid","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"B15-20240826","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1681\/ASN.2013101062","article-title":"The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: A systematic review","volume":"25","author":"Vanholder","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B16-20240826","first-page":"60","article-title":"Chronic kidney disease and fibrosis: The role of uremic retention solutes","volume":"2","author":"Mutsaers","year":"2015","journal-title":"Front Med (Lausanne)"},{"key":"B17-20240826","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/ki.2013.133","article-title":"Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway","volume":"84","author":"Gondouin","year":"2013","journal-title":"Kidney Int"},{"key":"B18-20240826","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1161\/CIRCULATIONAHA.112.118174","article-title":"Uremic serum and solutes increase post-vascular interventional thrombotic risk through altered stability of smooth muscle cell tissue factor","volume":"127","author":"Chitalia","year":"2013","journal-title":"Circulation"},{"key":"B19-20240826","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1681\/ASN.2014121241","article-title":"The aryl hydrocarbon receptor is a critical regulator of tissue factor stability and an antithrombotic target in uremia","volume":"27","author":"Shivanna","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B20-20240826","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aam8475","article-title":"Targeting STUB1-tissue factor axis normalizes hyperthrombotic uremic phenotype without increasing bleeding risk","volume":"9","author":"Shashar","year":"2017","journal-title":"Sci Transl Med"},{"key":"B21-20240826","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.3389\/fphys.2018.01623","article-title":"Indoxyl sulfate promotes arterial thrombosis in rat model via increased levels of complex TF\/VII, PAI-1, platelet activation as well as decreased contents of SIRT1 and SIRT3","volume":"9","author":"Karbowska","year":"2018","journal-title":"Front Physiol"},{"key":"B22-20240826","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1160\/TH08-10-0696","article-title":"Hypercoagulability is independently associated with kynurenine pathway activation in dialysed uraemic patients","volume":"102","author":"Pawlak","year":"2009","journal-title":"Thromb Haemost"},{"key":"B23-20240826","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1681\/ASN.2017080929","article-title":"Uremic solute-aryl hydrocarbon receptor-tissue factor axis associates with thrombosis after vascular injury in humans","volume":"29","author":"Kolachalama","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"B24-20240826","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41581-019-0172-1","article-title":"Intestinal microbiome and fitness in kidney disease","volume":"15","author":"Meijers","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"B25-20240826","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0098-2997(83)90005-5","article-title":"Biochemistry of tryptophan in health and disease","volume":"6","author":"Bender","year":"1983","journal-title":"Mol Aspects Med"},{"key":"B26-20240826","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1079\/NRR200133","article-title":"Tryptophan metabolism in alcoholism","volume":"15","author":"Badawy","year":"2002","journal-title":"Nutr Res Rev"},{"issue":"Pt B","key":"B27-20240826","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.neuropharm.2015.11.015","article-title":"Tryptophan availability for kynurenine pathway metabolism across the life span: Control mechanisms and focus on aging, exercise, diet and nutritional supplements","volume":"112","author":"Badawy","year":"2017","journal-title":"Neuropharmacology"},{"key":"B28-20240826","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/prot.22819","article-title":"Substrate stereo-specificity in tryptophan dioxygenase and indoleamine 2,3-dioxygenase","volume":"78","author":"Capece","year":"2010","journal-title":"Proteins"},{"key":"B29-20240826","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1369\/jhc.2009.953604","article-title":"Indoleamine 2,3-dioxygenase tissue distribution and cellular localization in mice: Implications for its biological functions","volume":"58","author":"Dai","year":"2010","journal-title":"J Histochem Cytochem"},{"key":"B30-20240826","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.4049\/jimmunol.179.8.5246","article-title":"Induction of indoleamine 2,3-dioxygenase in vascular smooth muscle cells by interferon-gamma contributes to medial immunoprivilege","volume":"179","author":"Cuffy","year":"2007","journal-title":"J Immunol"},{"key":"B31-20240826","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/j.1600-6143.2006.01324.x","article-title":"Expression of indoleamine 2,3-dioxygenase (IDO) by endothelial cells: Implications for the control of alloresponses","volume":"6","author":"Beutelspacher","year":"2006","journal-title":"Am J Transplant"},{"key":"B32-20240826","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/MOH.0b013e32832e9ddd","article-title":"Animal models of thrombosis","volume":"16","author":"Bodary","year":"2009","journal-title":"Curr Opin Hematol"},{"issue":"Suppl 2","key":"B33-20240826","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.thromres.2012.02.036","article-title":"Murine models of thrombosis","volume":"129","author":"Cooley","year":"2012","journal-title":"Thromb Res"},{"issue":"Suppl 1","key":"B34-20240826","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1016\/S0049-3848(08)70022-7","article-title":"Overview of murine thrombosis models","volume":"122","author":"Whinna","year":"2008","journal-title":"Thromb Res"},{"key":"B35-20240826","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1001\/jama.299.18.2164","article-title":"Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: A randomized controlled trial","volume":"299","author":"Dember","year":"2008","journal-title":"JAMA"},{"key":"B36-20240826","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/0735-1097(93)90755-P","article-title":"Two- and three-year results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II clinical trial","volume":"22","author":"Terrin","year":"1993","journal-title":"J Am Coll Cardiol"},{"key":"B37-20240826","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ddmod.2010.08.002","article-title":"Models of chronic kidney disease","volume":"7","author":"Yang","year":"2010","journal-title":"Drug Discov Today Dis Models"},{"key":"B38-20240826","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.vascn.2013.05.001","article-title":"New model for adenine-induced chronic renal failure in mice, and the effect of gum acacia treatment thereon: Comparison with rats","volume":"68","author":"Ali","year":"2013","journal-title":"J Pharmacol Toxicol Methods"},{"key":"B39-20240826","doi-asserted-by":"crossref","first-page":"F57","DOI":"10.1152\/ajprenal.00051.2015","article-title":"Chronic kidney disease induced by adenine: A suitable model of growth retardation in uremia","volume":"309","author":"Claramunt","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"B40-20240826","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1471-2369-14-116","article-title":"A novel model of adenine-induced tubulointerstitial nephropathy in mice","volume":"14","author":"Jia","year":"2013","journal-title":"BMC Nephrol"},{"key":"B41-20240826","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.kint.2019.09.029","article-title":"Temporal and tissue-specific activation of aryl hydrocarbon receptor in discrete mouse models of kidney disease","volume":"97","author":"Walker","year":"2020","journal-title":"Kidney Int"},{"key":"B42-20240826","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15761\/NRD.1000126","article-title":"Adenine-induced hyperphosphatemia in a murine model of renal insufficiency","volume":"2","author":"Bobeck","year":"2017","journal-title":"Nephrol Renal Dis"},{"key":"B43-20240826","doi-asserted-by":"crossref","first-page":"e0215717","DOI":"10.1371\/journal.pone.0215717","article-title":"Protective effects of gelsolin in acute pulmonary thromboembolism and thrombosis in the carotid artery of mice","volume":"14","author":"Gupta","year":"2019","journal-title":"PLoS One"},{"key":"B44-20240826","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11239-020-02337-8","article-title":"Aqueous extract of Whitmania pigra Whitman ameliorates ferric chloride-induced venous thrombosis in rats via antioxidation","volume":"52","author":"Li","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"B45-20240826","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.thromres.2020.08.040","article-title":"Knockdown of liver-derived factor XII by GalNAc-siRNA ALN-F12 prevents thrombosis in mice without impacting hemostatic function","volume":"196","author":"Liu","year":"2020","journal-title":"Thromb Res"},{"key":"B46-20240826","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1111\/jth.15298","article-title":"Mitochondrial reactive oxygen species scavenging attenuates thrombus formation in a murine model of sickle cell disease","volume":"19","author":"Annarapu","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"Suppl 1","key":"B47-20240826","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/S0049-3848(08)70025-2","article-title":"The role of smooth muscle derived tissue factor in mediating thrombosis and arterial injury","volume":"122","author":"Taubman","year":"2008","journal-title":"Thromb Res"},{"key":"B48-20240826","doi-asserted-by":"crossref","first-page":"6795","DOI":"10.1158\/0008-5472.CAN-17-2285","article-title":"Discovery of IDO1 inhibitors: From bench to bedside","volume":"77","author":"Prendergast","year":"2017","journal-title":"Cancer Res"},{"key":"B49-20240826","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12882-017-0457-1","article-title":"Indoxyl sulfate: The uremic toxin linking hemostatic system disturbances with the prevalence of cardiovascular disease in patients with chronic kidney disease","volume":"18","author":"Kami\u0144ski","year":"2017","journal-title":"BMC Nephrol"},{"key":"B50-20240826","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1093\/ndt\/gfn739","article-title":"Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: A possible link between chronic inflammation and uraemic symptoms","volume":"24","author":"Schefold","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"B51-20240826","doi-asserted-by":"crossref","first-page":"4855","DOI":"10.1038\/s41598-017-05121-6","article-title":"Altered KYN\/TRP, Gln\/Glu, and Met\/methionine sulfoxide ratios in the blood plasma of medication-free patients with major depressive disorder","volume":"7","author":"Umehara","year":"2017","journal-title":"Sci Rep"},{"key":"B52-20240826","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ccl.2005.04.004","article-title":"Vascular access in hemodialysis: Issues, management, and emerging concepts","volume":"23","author":"Roy-Chaudhury","year":"2005","journal-title":"Cardiol Clin"},{"key":"B53-20240826","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1046\/j.1523-1755.2001.00750.x","article-title":"Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts","volume":"59","author":"Roy-Chaudhury","year":"2001","journal-title":"Kidney Int"},{"key":"B54-20240826","first-page":"150","article-title":"Biology of arteriovenous fistula failure","volume":"20","author":"Roy-Chaudhury","year":"2007","journal-title":"J Nephrol"},{"key":"B55-20240826","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jvs.2015.07.086","article-title":"Multiple preoperative and intraoperative factors predict early fistula thrombosis in the Hemodialysis Fistula Maturation Study","volume":"63","author":"Farber","year":"2016","journal-title":"J Vasc Surg"},{"key":"B56-20240826","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1056\/NEJM198903093201002","article-title":"Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial","volume":"320","year":"1989","journal-title":"N Engl J Med"},{"key":"B57-20240826","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.3389\/fpsyg.2017.01561","article-title":"The relationships among tryptophan, kynurenine, indoleamine 2,3-dioxygenase, depression, and neuropsychological performance","volume":"8","author":"Hestad","year":"2017","journal-title":"Front Psychol"},{"key":"B58-20240826","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/2048872615574106","article-title":"Impact of acute coronary syndromes on survival of dialysis patients following surgical or percutaneous coronary revascularization in the United States","volume":"5","author":"Shroff","year":"2016","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"B59-20240826","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nature06797","article-title":"Triggers, targets and treatments for thrombosis","volume":"451","author":"Mackman","year":"2008","journal-title":"Nature"},{"key":"B60-20240826","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1161\/ATVBAHA.117.309846","article-title":"Tissue factor: An essential mediator of hemostasis and trigger of thrombosis","volume":"38","author":"Grover","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B61-20240826","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.2174\/092986711795656072","article-title":"Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases","volume":"18","author":"Prendergast","year":"2011","journal-title":"Curr Med Chem"},{"key":"B62-20240826","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1053\/j.ajkd.2018.09.012","article-title":"Use of measures of inflammation and kidney function for prediction of atherosclerotic vascular disease events and death in patients with CKD: Findings from the CRIC Study","volume":"73","author":"Amdur","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"B63-20240826","doi-asserted-by":"crossref","first-page":"327","DOI":"10.5414\/CNP60327","article-title":"Interleukin-18, interleukin-18 binding protein and impaired production of interferon-gamma in chronic renal failure","volume":"60","author":"Lonnemann","year":"2003","journal-title":"Clin Nephrol"},{"key":"B64-20240826","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fimmu.2018.00151","article-title":"The role of indoleamine-2,3-dioxygenase in cancer development, diagnostics, and therapy","volume":"9","author":"Horny\u00e1k","year":"2018","journal-title":"Front Immunol"},{"key":"B65-20240826","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.3389\/fimmu.2019.01801","article-title":"Limitations and off-target effects of tryptophan-related IDO inhibitors in cancer treatment","volume":"10","author":"G\u00fcnther","year":"2019","journal-title":"Front Immunol"},{"key":"B66-20240826","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/nbt.4180","article-title":"Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme","volume":"36","author":"Triplett","year":"2018","journal-title":"Nat Biotechnol"},{"key":"B67-20240826","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1681\/ASN.2012050536","article-title":"Cognitive disorders and dementia in CKD: The neglected kidney-brain axis","volume":"24","author":"Bugnicourt","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"B68-20240826","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1182\/blood-2018-08-868067","article-title":"Neutrophils, NETs, and immunothrombosis","volume":"132","author":"Grover","year":"2018","journal-title":"Blood"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.2020091310","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:30:19Z","timestamp":1786131019000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.2020091310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":68,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2020091310","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"2020-09-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}